InnoCare Pharma Limited
INCPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,009,448 | $738,537 | $625,404 | $1,043,033 |
| % Growth | 36.7% | 18.1% | -40% | – |
| Cost of Goods Sold | $138,441 | $128,435 | $143,397 | $65,667 |
| Gross Profit | $871,007 | $610,102 | $482,007 | $977,366 |
| % Margin | 86.3% | 82.6% | 77.1% | 93.7% |
| R&D Expenses | $814,027 | $751,176 | $639,139 | $721,584 |
| G&A Expenses | $47,872 | $48,573 | $50,999 | $46,197 |
| SG&A Expenses | $310,643 | $252,126 | $613,272 | $344,660 |
| Sales & Mktg Exp. | $262,771 | $203,553 | $258,550 | $298,463 |
| Other Operating Expenses | $272,121 | $257,954 | $0 | $74,753 |
| Operating Expenses | $1,396,791 | $1,261,256 | $1,252,411 | $1,140,997 |
| Operating Income | -$525,784 | -$651,154 | -$770,404 | -$181,104 |
| % Margin | -52.1% | -88.2% | -123.2% | -17.4% |
| Other Income/Exp. Net | $73,191 | $6,948 | -$123,323 | $160,983 |
| Pre-Tax Income | -$452,593 | -$644,206 | -$893,727 | -$20,121 |
| Tax Expense | $263 | $1,426 | $0 | $46,558 |
| Net Income | -$440,633 | -$631,263 | -$886,593 | -$64,545 |
| % Margin | -43.7% | -85.5% | -141.8% | -6.2% |
| EPS | -0.26 | -0.37 | -0.6 | -0.037 |
| % Growth | 29.7% | 38.3% | -1,539.3% | – |
| EPS Diluted | -0.26 | -0.37 | -0.6 | -0.037 |
| Weighted Avg Shares Out | 1,690,850 | 1,706,116 | 1,479,565 | 1,764,321 |
| Weighted Avg Shares Out Dil | 1,690,850 | 1,706,116 | 1,479,565 | 1,764,321 |
| Supplemental Information | – | – | – | – |
| Interest Income | $171,589 | $192,333 | $136,914 | $135,135 |
| Interest Expense | $33,788 | $35,031 | $17,045 | $2,642 |
| Depreciation & Amortization | $106,260 | $92,621 | $68,403 | $15,325 |
| EBITDA | -$312,545 | -$516,554 | -$808,279 | -$167,203 |
| % Margin | -31% | -69.9% | -129.2% | -16% |